Mira Dx Licenses Triple Negative Breast Cancer Risk Variant From Yale University
 

Mira Dx announced that it has licensed technology from Yale University based on the acceptance of a pivotal breast cancer study in the January issue of the journal Cell Cycle. While numerous BRCA1 coding sequence mutations are associated with breast cancer risk, such mutations in BRCA1 account for less than 5% of breast cancer risk...

More...